Abstract

Tetracycline analogues (TCNAs) have been shown to inhibit matrix metalloproteinases and to induce apoptosis in several cancer cell types. In the present study, the cytotoxic effects of TCNAs doxycycline (DOXY), minocycline (MINO) and chemically modified tetracycline-3 (COL-3) were investigated in the human acute myeloid leukemia HL-60 cell line. Cells were incubated with TCNAs in final concentrations of 0.5–100 µg/ml for 24 h. Viability of the leukemic cells was inhibited in a concentration-dependent manner using resazurin assay. The estimated IC50s were 9.2 µg/ml for DOXY, 9.9 µg/ml for MINO and 1.3 µg/ml for COL-3. All three TCNAs induced potent cytotoxic effects and cell death. Apoptosis, which was assessed by morphological changes and annexin V positivity, was concentration- and time-dependent following incubation with any one of the drugs. TCNAs induced DNA double strand breaks soon after treatment commenced as detected by γH2AX and western blot. The loss of mitochondrial membrane potential (Δψm), caspase activation and cleavage of PARP and Bcl-2 were observed; however, the sequence of events differed among the drugs. Pancaspase inhibitor Z-VAD-FMK improved survival of TCNAs-treated cells and decreased TCNAs-induced apoptosis. In summary, we demonstrated that TCNAs had a cytotoxic effect on the HL-60 leukemic cell line. Apoptosis was induced via mitochondria-mediated and caspase-dependent pathways in HL-60 cells by all three TCNAs. COL-3 exerted the strongest anti-proliferative and pro-apoptotic effects in concentrations that have been achieved in human plasma in reported clinical trials. These results indicate that there is a therapeutic potential of TCNAs in leukemia.

Highlights

  • Leukemia is a heterogeneous group of hematopoietic malignancies with worldwide distribution

  • We investigated the cytotoxic effects of Tetracycline analogues (TCNAs) DOXY, MINO and chemically modified tetracycline-3 (COL-3) in the human myeloid leukemia cell line HL-60 that was originally established and classified as acute promyelocytic leukemia

  • We report that TCNAs reduced the viability of the HL-60 cells in a concentrationdependent manner

Read more

Summary

Introduction

Leukemia is a heterogeneous group of hematopoietic malignancies with worldwide distribution. The benefits of intensive therapy are often neutralized by increased therapy related mortality. Despite a better understanding of the unique biological and clinical features of AML in older patients, and development of new drugs, the co-morbidities and high susceptibility to treatment-related toxicity still limit treatment success [6]. New treatment strategies are needed in order to maximize the therapeutic benefit and minimize treatment-related toxicity in this population. Those strategies may consist of better selection of patients who tolerate and benefit from intensive induction chemotherapy, as well as the development of novel agents, or a combination of both

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call